TYK2 and psoriasis: The only small-molecule drug approved by the FDA in 2022 for the treatment of psoriasis in adults is deucravacitinib, which inhibits a tyrosine kinase 2 (TYK2) mediating IL-23, IL-12, and IFN type I signaling [23].